Page last updated: 2024-12-07

n-benzyl-4-toluidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID79403
CHEMBL ID237424
SCHEMBL ID171785
MeSH IDM0136406

Synonyms (42)

Synonym
EN300-11944
einecs 226-455-7
n-benzyl-p-toluidine
nsc 8084
x1uci3s8j8 ,
unii-x1uci3s8j8
nsc-8084
nsc8084
5405-15-2
n-benzyl-n-(4-methylphenyl)amine
benzenemethanamine, n-(4-methylphenyl)-
OPREA1_065186
MLS001033459
smr000385588
n-benzyl-4-methylaniline
CHEMBL237424
AKOS000241641
HMS1719M17
n-benzyl-4-toluidine
NCGC00246111-01
HMS2724F10
SCHEMBL171785
n-(4-methylphenyl)benzylamine
n-(4-methylphenyl)-n-benzylamine
n-(4-tolyl)benzylamine
Z57051057
DTXSID10202376
benzyl-p-tolyl-amine
mfcd00870620
J-515772
bdbm50489072
n-(4-methylphenyl)benzenemethanamine
4-methyl-n-benzylaniline
n-(p-tolyl)benzylamine
benzyl(4-methylphenyl)amine
n-(p-methylphenyl)benzylamine
p-toluidine, n-benzyl-
n-benzyl-4-methylbenzenamine
E78551
n-benzyl-3-(ethoxycarbonyl)-4-piperidone hydrochloride
BS-48822
CS-0224446
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency8.97165.623417.292931.6228AID485281; AID489008
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency5.01190.100020.879379.4328AID588453
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency10.00000.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
huntingtin isoform 2Homo sapiens (human)Potency5.62340.000618.41981,122.0200AID1688
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID381974Cytotoxicity against human PC3 cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent.
AID301909Growth inhibition of mouse L929 cells after 5 days by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Efficient one-pot synthesis of biologically active polysubstituted aromatic amines.
AID381973Cytotoxicity against human LNCaP cells after 5 days by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent.
AID381975Down regulation of androgen receptor expression in human LNCaP cells by Western blot analysis2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent.
AID301911Growth inhibition of mouse L929 cells below 40 ug/mL after 5 days by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Efficient one-pot synthesis of biologically active polysubstituted aromatic amines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's2 (16.67)18.2507
2000's3 (25.00)29.6817
2010's5 (41.67)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.26 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]